On May 27, Intuitive Surgical fell 3.2% in regular trading, trading at $422.5 per share, with trading volume of $352 million.

On the news front, Goldman Sachs lowered its target price on Intuitive Surgical from $621 to $558, a reduction of approximately 10%, while maintaining a Buy rating. According to FactSet, the stock carries an average analyst rating of Overweight with a mean price target of $575.70.

The broader Health Care Equipment sector also showed weakness during the session. Among sector peers, Boston Scientific fell 10.24%, Stryker fell 0.95%, Abbott Laboratories fell 0.82%, Medtronic fell 0.95%, and Edwards Lifesciences fell 0.49%.

Intuitive Surgical is the global leader in robotic-assisted minimally invasive care, offering the da Vinci Surgical System for complex surgery and the Ion endoluminal system for minimally invasive lung biopsies. The company provides integrated digital capabilities and progressive learning pathways supporting its technology ecosystem.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)